Airain ltd acquired a new stake in shares of Heron Therapeutics, Inc. (NASDAQ:HRTX) during the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm acquired 31,943 shares of the biotechnology company’s stock, valued at approximately $442,000.
Other hedge funds and other institutional investors have also recently made changes to their positions in the company. Wells Fargo & Company MN raised its holdings in shares of Heron Therapeutics by 78.8% during the 1st quarter. Wells Fargo & Company MN now owns 39,579 shares of the biotechnology company’s stock valued at $595,000 after buying an additional 17,442 shares in the last quarter. FMR LLC raised its holdings in shares of Heron Therapeutics by 36.7% during the 1st quarter. FMR LLC now owns 8,030,880 shares of the biotechnology company’s stock valued at $120,464,000 after buying an additional 2,158,041 shares in the last quarter. Point72 Asset Management L.P. purchased a new position in Heron Therapeutics in the 1st quarter worth approximately $2,002,000. Tang Capital Management LLC increased its stake in Heron Therapeutics by 39.7% in the 1st quarter. Tang Capital Management LLC now owns 8,654,914 shares of the biotechnology company’s stock worth $129,824,000 after purchasing an additional 2,457,716 shares during the period. Finally, Swiss National Bank increased its stake in Heron Therapeutics by 39.9% in the 1st quarter. Swiss National Bank now owns 72,600 shares of the biotechnology company’s stock worth $1,089,000 after purchasing an additional 20,700 shares during the period.
Heron Therapeutics, Inc. (HRTX) traded down 0.33% during trading on Thursday, hitting $15.15. The stock had a trading volume of 392,948 shares. Heron Therapeutics, Inc. has a 12 month low of $12.21 and a 12 month high of $20.85. The stock has a 50 day moving average price of $15.81 and a 200-day moving average price of $14.97. The stock’s market cap is $820.19 million.
Heron Therapeutics (NASDAQ:HRTX) last issued its quarterly earnings results on Wednesday, August 9th. The biotechnology company reported ($0.80) earnings per share for the quarter, topping the consensus estimate of ($0.90) by $0.10. The business had revenue of $8.51 million during the quarter, compared to analysts’ expectations of $4.53 million. On average, equities analysts predict that Heron Therapeutics, Inc. will post ($3.51) EPS for the current year.
A number of equities analysts have commented on the company. BidaskClub raised Heron Therapeutics from a “sell” rating to a “hold” rating in a research note on Saturday, August 26th. Cantor Fitzgerald set a $31.00 price target on Heron Therapeutics and gave the stock a “buy” rating in a research note on Friday, August 18th. Jefferies Group LLC reaffirmed a “buy” rating on shares of Heron Therapeutics in a research note on Wednesday, August 16th. Noble Financial reaffirmed a “buy” rating on shares of Heron Therapeutics in a research note on Thursday, August 10th. Finally, Cowen and Company set a $40.00 price target on Heron Therapeutics and gave the stock a “buy” rating in a research note on Thursday, August 3rd. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating and ten have issued a buy rating to the company. The stock currently has an average rating of “Buy” and a consensus target price of $29.25.
TRADEMARK VIOLATION WARNING: This article was originally reported by BBNS and is the property of of BBNS. If you are viewing this article on another website, it was stolen and republished in violation of U.S. & international trademark and copyright laws. The correct version of this article can be accessed at https://baseballnewssource.com/markets/airain-ltd-takes-position-in-heron-therapeutics-inc-hrtx/1588496.html.
Heron Therapeutics Company Profile
Heron Therapeutics, Inc is a biotechnology company engaged in developing pharmaceutical products for patients suffering from cancer or pain. The Company’s product candidates include SUSTOL, HTX-019 and HTX-011. All of its product candidates utilize science and technology platforms, including its Biochronomer drug delivery technology.
Receive News & Ratings for Heron Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Heron Therapeutics Inc. and related companies with our FREE daily email newsletter.